AVERT

(redirected from avertable)
Also found in: Dictionary, Thesaurus, Legal.

AVERT

Cardiology Atorvastatin VErsus Revascularization Treatments. A trial comparing the efficacy of aggressive lowering of cholesterol in patients at risk of future cardiovascular events (ischaemic heart disease and stable angina) to percutaneous coronary intervention.
Conclusion Atorvastatin evoked a 46% reduction in LDL-C compared to an 18% reduction with revascularization; ischaemic events were 36% lower with atorvastatin than with revascularisation; the first ischaemic event occurred after a much longer time in atorvastatin patients. Aggressive LDL-C lowering in patients with stable CAD results in a markedly reduced risk of cardiovascular events (nonfatal heart attack, bypass surgery, revascularization, and worsening angina) compared with patients receiving angioplasty followed by usual care. In AVERT, 13% of patients treated with atorvastatin suffered a cardiovascular event compared with 21% of patients receiving angioplasty and usual care.
Cardiovascular surgery Artificial Valve Endocarditis Reduction Trial. A trial comparing the St. Jude masters series valve with silver (Silzone) coated sewing cuff with the St Judes mechanical heart valve with uncoated cuff
Logistics Randomised, multicenter.
Conclusion Trial was stopped in 2000, when 807 patients had been randomised, because of an increased risk of major paravalvular leak leading to valve explant in the Silzone arm of the study.

AVERT

Cardiology
1. A clinical trial—Atorvastatin Versus Revascularization Treatments–which evaluated the efficacy of aggressive lowering of cholesterol in Pts at risk of future cardiovascular events.
2. A clinical trial–Artificial Valve Endocarditis Reduction Trial.
References in periodicals archive ?
In other words, whereas NQF chose conditions that were avoidable, the result of hospital mistakes, and avertable through the adoption of simple guidelines; CMS chose a condition that is common, unavoidable and the often, contracted despite proper hospital care.
Avertable burden, cost-effectiveness and affordability provide only three dimensions of the information necessary for decisions about vaccine adoption.